The treatment paradigm for second- and subsequent-line advanced or metastatic colorectal cancer revolves around targeted agents (such as Erbitux, Vectibix, and Avastin) with or without chemotherapy regimens. The 2017 FDA approvals of Keytruda and Opdivo have expanded treatment options for the minority of patients with MSI-H or dMMR metastatic colorectal cancer. Although the market landscape is evolving at a rapid pace, significant unmet need exists for the development of well-tolerated agents that can improve overall survival and progression-free survival outcomes.
Questions Answered
Product Description
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, France, Germany, and the United Kingdom.
Primary research: Survey of 62 U.S. and 30 European medical oncologists fielded in March 2018.
Key companies: Roche/Genentech, Eli Lilly/Merck KGaA, Amgen, Taiho Pharmaceutical, Merck & Co., and Bristol-Myers Squibb.
Key drugs: Avastin, Erbitux, Vectibix, Lonsurf, Keytruda, and Opdivo.